Summary of the evidence on fluticasone furoate, umeclidinium and vilanterol (Trelegy) for chronic obstructive pulmonary disease (COPD) to inform local NHS
Summary of the evidence on buprenorphine prolonged-release subcutaneous injection (Buvidal) for opioid dependence to inform local NHS
Summary of the evidence on doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy in women aged 18 years and older to inform local NHS
Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making
Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis
Summary of the evidence on beclometasone, formoterol and glycopyrronium (Trimbow) for chronic obstructive pulmonary disease (COPD) to inform local NHS planning
Summary of the evidence on antimicrobial prescribing: imipenem with cilastatin and relebactam
Summary of the evidence on antimicrobial prescribing: cefiderocol
Summary of the evidence on antimicrobial prescribing: delafloxacin
ES24 . Key messages The content of this evidence review was up-to-date
ES25 . Key messages The content of this evidence review was up-to-date on 20 April 2020. See summaries of product characteristics
ES26 . Key messages The content of this evidence review was up-to-date on 13 May 2020. See summaries of product characteristics
ES23 . Key messages The content of this evidence review was up-to-date
ES27 . Key messages The content of this evidence review was up-to-date on 4 June 2020. See summaries of product characteristics
ES33 Product overview The content of this evidence summary was up to date in January 2021. See summaries of product characteristics
This evidence summary has been updated and replaced by the COVID-19 rapid guideline on vitamin D (NG187).